Overview

Upfront Combination Pulmonary Arterial Hypertension Therapy

Status:
Recruiting

Trial end date:
2021-01-31

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of first-line combination therapy using riociguat with ambrisentan in patients with Pulmonary Arterial Hypertension (PAH).

Phase:

Phase 4

Details

Lead Sponsor:

University of Calgary

Collaborator:

Bayer

Treatments:

Ambrisentan
Riociguat